BBS-Bioactive Bone Substitutes Plc

The Prospectus of Rights Issue has been published on the Company’s website today

Company Announcement, Insider Information 29 May 2020 at 11:00 am (UTC +3:00)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, SINGAPORE, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

The Prospectus related to the rights issue (the “Offering”) totaling approximately EUR 5.5 million issued by BBS-Bioactive Bone Substitutes Plc (“BBS” or “Company”) on 26 May 2020 has been published.
The official Finnish language version of the prospectus is available on BBS’ website (https://www.bbs-artebone.fi/sijoittajille/osakeanti-2020/) as well as its unofficial English language translation, including a Swedish summary on (https://www.bbs-artebone.fi/investors/share-issue-2020), on the website of Aalto Capital Partners Oy (www.aaltocapital.com), on the website of Evli Pankki Oyj (www.evli.com) and on the website of Hagberg & Aneborn Fondkommission AB (http://www.hagberganeborn.se/) from this day on.

Advisers

Aalto Capital Partners Oy ("Aalto Capital") is acting as financial advisor to the Company in the Offering. Smartius Oy is acting as the legal adviser to the Company on aspects of the Offering related to the Finnish law.

For more information:

BBS-Bioactive Bone Substitutes Plc
CEO Ilkka Kangasniemi
Phone: [phone]
E-mail: [e-mail]

This is information that BBS-Bioactive Bone Substitutes Plc is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on 29 May 2020 at 11:00 am (UTC +3.00).

About BBS
BBS-Bioactive Bone Substitutes Plc is a Finnish orthobiologic biotech company. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for orthopaedic surgery. The research and development in the field of medicine requires perseverance and courage to develop new things.  We have over 20 years of expertise in this. Our operations are characterised by top expertise, innovativeness and dedicated and committed employees. The first product, ARTEBONE Paste, is ready and the application process for the CE marking enabling commercialization is in progress.
More information: www.bbs-artebone.fi.

The company’s Certified Adviser Stockholm Certified Advisers AB, p. [phone], [e-mail]

IMPORTANT NOTICE
This release or the information contained therein shall not be published or distributed, directly or indirectly, in the United States, Canada, Australia, Hong Kong, Singapore, New Zealand, South Africa or Japan or any other jurisdiction where such publication or distribution is unlawful. The information contained in this release does not constitute an offer of, or invitation to purchase any securities in any area, where offering, procurement of or selling such securities would be unlawful prior to registration or exemption from registration or any other approval required by the securities regulation in such area. This release is not an offer for sale of securities in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended, and the rules and regulations issued by virtue of it. BBS has not registered, and does not intend to register, any offering of securities in the United States. No actions have been taken to register the shares or the offering anywhere else than in Finland and Sweden.
The information contained herein shall not constitute an offer of, or invitation to purchase any securities in any jurisdiction. This release is not a prospectus and does not constitute any offer, invitation or investment advice to subscribe for or purchase securities. Investors should not subscribe for or purchase any securities or make any investment decisions referred to herein except on the basis of information contained in a prospectus issued by BBS.